Table 2. Prognostic information among models used in terms of DFS.

DFS	N of patients	N of events	CTS (8 df)		RRS (1 df)		AOS (1 df)		CTS+RRS (9 df)		CTS+AOS (9 df)		CTS+RRS vs. CTS (1 df)		CTS+AOS vs. CTS (1 df)
			LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	p	LR-Δχ2	P	LR-Δχ2	p
All patients	875	316	65.1	<0.001	0.8	0.38	53.2	0.14	66.2	<0.001	73.8	<0.001	1.1	0.29	8.7	0.003
By IHC subtype
Luminal A	201	55	12.6	0.083	1.6	0.21	10.4	0.001	14.8	0.062	17.4	0.026	2.3	0.13	4.8	0.028
Luminal B	313	118	32.2	<0.001	0.6	0.42	16.0	<0.001	33.6	<0.001	37.0	<0.001	1.3	0.24	4.8	0.029
Luminal-HER2	109	45	10.8	0.15	0.5	0.48	9.2	0.002	10.9	0.21	12.3	0.14	0.1	0.81	1.5	0.23
HER2-Enriched	87	31	11.1	0.14	<0.1	0.83	1.6	0.20	11.4	0.18	11.1	0.20	0.4	0.55	<0.1	0.94
Triple-negative	96	43	7.6	0.37	<0.1	0.83	7.1	0.008	7.6	0.47	9.8	0.28	<0.1	>0.99	2.2	0.14
By HER2 status
HER2-positive	196	76	16.5	0.021	0.4	0.53	10.0	0.002	16.5	0.036	17.6	0.025	<0.1	0.98	1.0	0.31
HER2-negative	621	220	46.3	<0.001	3.2	0.072	37.7	<0.001	49.8	<0.001	56.5	<0.001	3.5	0.060	10.2	0.001
By nodal status (-1 df for CTS)
0–3	351	75	5.6	0.47	0.8	0.38	2.4	0.12	6.1	0.53	5.8	0.56	0.5	0.50	0.2	0.64
>3	524	241	7.6	0.27	0.5	0.50	12.3	0.001	8.3	0.31	16.9	0.018	0.7	0.39	9.3	0.002

Patients were classified to breast cancer subtypes defined by immunohistochemistry as follows: Luminal A (ER-positive and/or PgR-positive, HER2-negative, Ki67^low); Luminal B (ER-positive and/or PgR-positive, HER2-negative, Ki67^high); Luminal-HER2 (ER-positive and/or PgR-positive, HER2-positive); HER2-enriched (ER-negative, PgR-negative, HER2-positive); and triple-negative breast cancer (TNBC) (ER-negative, PgR-negative, HER2-negative).

DFS, disease-free survival; N, number; CTS, clinical treatment score; RRS, risk for recurrence score; AOS, adjuvant online score IHC, immunohistochemistry.